Reviewer's report

Title: CYP39A1 polymorphism protects against toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer

Version: 2  Date: 24 July 2015

Reviewer: Wan Teck Lim

Reviewer's report:

The study is a small one which attempts to link toxicity due to docetaxel in a 3 drug induction regimen to a particular CYP39A1 polymorphism. There is no supportive pharmacokinetic data in the study to suggest that patients who carried the variant have higher exposure to docetaxel compared to those who don’t.